Terms: = Breast cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Staging
5 results:
1. Clinicopathologic Features and Immune Cell Subtypes Analysis of Tumor-infiltrating Lymphocytes Rich Invasive breast Carcinoma of No Special Type.
Zhao Y; Huang T; Jin X; Gong XM; Lu YZ
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):354-362. PubMed ID: 37278279
[TBL] [Abstract] [Full Text] [Related]
2.
Banin Hirata BK; Losi Guembarovski R; Vitiello GAF; Guembarovski AL; Brajão de Oliveira K; Watanabe MAE
Dis Markers; 2017; 2017():6359603. PubMed ID: 28713192
[No Abstract] [Full Text] [Related]
3. Molecular markers for breast cancer: prediction on tumor behavior.
Banin Hirata BK; Oda JM; Losi Guembarovski R; Ariza CB; de Oliveira CE; Watanabe MA
Dis Markers; 2014; 2014():513158. PubMed ID: 24591761
[TBL] [Abstract] [Full Text] [Related]
4. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.
Ladoire S; Mignot G; Dabakuyo S; Arnould L; Apetoh L; Rébé C; Coudert B; Martin F; Bizollon MH; Vanoli A; Coutant C; Fumoleau P; Bonnetain F; Ghiringhelli F
J Pathol; 2011 Jul; 224(3):389-400. PubMed ID: 21437909
[TBL] [Abstract] [Full Text] [Related]
5. Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors.
Zlobec I; Lugli A
World J Gastroenterol; 2009 Dec; 15(47):5898-906. PubMed ID: 20014453
[TBL] [Abstract] [Full Text] [Related]
